옵션 체인은 다양한 행사가격과 만기일에 대한 Globus Medical의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Globus Medical에 대한 시장 심리를 평가합니다..

Globus Medical (NYSE:GMED) 주식, 옵션 체인

Globus Medical

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.

Earnings

Equities

News

Pre-Market Outlook

Markets

GMED

QCOM

SMCI

미국 주식 선물이 수요일 아침 (현지 시간 기준) 상승세를 보이는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식들이 다음과 같다: 1. CVS 헬스(NYSE:CVS)가 분기 이익을 주당 1.53달러, 매출을 927억 5천만 달러로 예상하는 가운데, 월스트리트는 개장 전 발표를 기다리고 있다. CVS 헬스의 주가는 애프터 마켓에서 0.7% 상승해 55.70달러로 거래되었다.

수요일 주목해야 할 주식: CVS 헬스, 글로버스 메디컬, 존슨 컨트롤스, 퀄컴 및 슈퍼 마이크로

Globus Medical, Inc. Class A Common Stock

Globus Medical Inc

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/11/05/final-trades-comerica-amazon-disney-leidos-holdings-and-dupont.html">Halftime Report Final Trades</a>,&#8221; Rob Sechan of NewEdge Wealth named Comerica Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) as <a href="https://www.benzinga.com/quote/CMA">his final trade</a>.
On Nov. 5, Comerica declared dividends and announced an increase in share repurchase authorization.
Jim Lebenthal of Cerity Partners said he is picking Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) for its all-weather capabilities.
Amazon.com's Amazon Prime Video recently unveiled an X-Ray Recaps feature to help users stay updated on their favorite shows, even after long breaks between episodes. Instead of rewinding or searching for plot summaries, viewers can now access spoiler-free, AI-generated recaps to <a href="https://www.benzinga.com/news/24/11/41739915/amazon-takes-on-netflix-with-new-ai-recaps">refresh their memory quickly.</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC named The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), saying that she believes in America's ability to spend, no matter what's the outcome of U.S. elections.
Walt Disney recently announced the creation of a new group, the Office of Technology Enablement (OTE), dedicated to guiding the company's approach to emerging technologies like artificial intelligence (AI) and extended reality (XR).
Bill Baruch of Blue Line Capital picked Leidos Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>).
On Oct. 29, Leidos reported third-quarter fiscal 2024 revenue growth of 7% year-over-year to $4.19 billion, beating the analyst consensus estimate of $4.07 billion. Demand across all customer segments, especially for managed health services, drove the growth.
Stephanie Link of Hightower Advisors picked DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>), which topped earnings expectations for the latest quarter.
On Nov. 5, the company reported sales growth of 4% year over year to $3.192 billion, missing the consensus of $3.204 billion. Organic sales increased +3% YoY, with a 5% increase in volume offset by a 2% decrease in price.
Price Action:
<ul>
<li>Comerica shares gained 1.4% to close at $63.28 during Tuesday's session.</li>
<li>Amazon shares rose 1.9% to settle at $199.50 during Tuesday's session.</li>
<li>Disney shares gained 0.9% to close at $96.63 on Tuesday.</li>
<li>DuPont shares gained 4.7% to settle at $85.67.</li>
<li>Leidos shares gained 2% to settle at $190.07 on Tuesday.</li>
</ul>
Check This Out:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

Trading Ideas

AMZN

LDOS

Amazon, Disney, DuPont, Leidos And A Financial Stock On CNBC's 'Final Trades'

WIIM

Aurora Cannabis shares are trading lower. The company reported Q2 financial results.

VTOL

Bristow Group shares are trading higher after the company reported better-than-expected Q3 EPS results.

Editor&#8217;s note: The story has been updated with additional details about Polymarket.
The French &#8216;Trump whale&#8217; known as Theo has successfully netted a profit of almost $50 million on several bets related to Donald Trump winning <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41766848/bitcoin-dogecoin-spike-after-trumps-speech-in-florida-winning-key-battle-states-puts-ex-pr">the 2024 presidential election</a>.
What Happened: The &#8216;<a href="https://www.thesupermodel.com/p/fredi9999-tracker">Fredi tracker</a>&#8216; monitoring the several accounts linked to the same pseudonymous Frenchman, shows Theo's total gains reaching almost $49.5 million, with his current portfolio value at $100.7 million on prediction market platform Polymarket.
Operating under aliases like Fredi9999, Theo4, PincessCaro, Michie, and RepTrump, his accounts have bet on various topics, including Donald Trump winning the electoral college, the popular vote, the state of Pennsylvania and other Trump-related bets.
Anonymous trader zxgngl, focused exclusively on Trump's election victory, netted $11.4 million. The third largest gainer, walletmobile, also bet solely on a Trump win, profiting $6.1 million.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">Bitcoin&#8217;s Future Under President-Elect Donald Trump: A Look At His Crypto Policies</a>
Why It Matters: Since early October, Theo and his linked accounts have significantly impacted the betting landscape. Initially, his five accounts held a combined position of $6.4 million, with total investments growing to $52 million by the end of October.
In an interview, Theo estimated <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41754690/worlds-largest-political-bettor-gives-donald-trump-a-90-chance-of-winning-election-citing-">Trump's chances of winning at 90%,</a> with a 65% likelihood of securing the popular vote. The prediction proved to be prescient, as the former President has become the President-elect and become the first Republican candidate to win the popular vote since George Bush in 2004.
What&#8217;s Next: The influence of&nbsp;prediction markets is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41766547/trump-gives-victory-speech-in-florida-as-winning-pennsylvania-puts-him-at-brink-of-victory-vows-to-f">Trump Gives Victory Speech In Florida As Winning Pennsylvania Puts Him At Brink Of Victory, Vows To &#8216;Fix Everything About Our Country&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Donald Trump's Re-Election Nets French 'Trump Whale' Almost $50 Million On Polymarket (UPDATED)

Cantor Fitzgerald analyst Troy Jensen reiterates Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) with a Underweight and maintains $12 price target.

Price Target

Reiteration

Analyst Ratings

XMTR

Cantor Fitzgerald Reiterates Underweight on Xometry, Maintains $12 Price Target

Cannabis reform faced a challenging moment in the 2024 U.S. elections, with several key state initiatives falling short and delivering a setback to advocates and industry players alike. Despite high hopes, the results painted a mixed, often sobering picture of regional attitudes toward cannabis reform. Here's a look at each state's journey, the measures they considered and what these outcomes signify for the cannabis community and the future of legalization efforts nationwide.
<h3 class="wp-block-heading">Florida</h3>
Florida's Amendment 3, which sought to legalize cannabis for adult use, gained 55.9% support but fell short of the required 60% threshold for constitutional amendments. 
Despite support from high-profile advocates, including former President Donald Trump, the initiative faced consistent opposition from GOP figures like Governor Ron DeSantis. Leading up to the election, DeSantis held conferences opposing the measure, with additional opposition funded by the state's transportation department. Although disappointed, industry leaders like Anthony Coniglio of NewLake Capital Partners (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NLCP#OTC">NLCP</a>) expressed optimism, noting, "It's important to recognize the bipartisan voter support that the measure received."
<h3 class="wp-block-heading">Nebraska</h3>
Nebraska saw a significant shift in policy with the passage of two medical cannabis measures. Initiative 437, which enacts the Nebraska Medical Cannabis Protection Act, allows patients to use cannabis to manage health conditions. Initiative 438, the Nebraska Medical Cannabis Regulation Act, establishes a commission to regulate the medical cannabis market.
"Following the adoption of the Commission&#8217;s regulations, the market may open as early as Summer 2026," explained Paula Savchenko, founding partner of Cannacore Group. This long-awaited result, driven by activist efforts and significant public support, signals a new era for medical cannabis in the state.
<h3 class="wp-block-heading">North Dakota</h3>
For the third time, North Dakota voters declined to legalize adult-use cannabis, with 53% voting against Measure 5. Despite advocating for financial benefits and regulatory structures similar to neighboring states, proponents couldn't secure enough support. 
Curaleaf (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>)'s CEO, Boris Jordan, remarked, "Curaleaf remains committed to advocating for responsible cannabis access and education." North Dakota's vote reflects a conservative stance that contrasts with the broader national trend toward legalization.
<h3 class="wp-block-heading">South Dakota</h3>
South Dakota also opted against legalizing cannabis for adult use with Measure 29, which fell short in a close vote. The measure had proposed limited possession rights and cultivation for adults over 21. 
Local industry voices like John Mueller, co-founder of Greenlight, described the outcome as "a missed opportunity," highlighting the potential economic benefits South Dakota could have reaped from a legal cannabis market. With similar measures failing in past elections, South Dakota's stance remains firmly anti-legalization, though advocates are hopeful for future progress.
<h3 class="wp-block-heading">Dallas, Texas</h3>
In a landmark decision, Dallas voters approved the "Dallas Freedom Act" to decriminalize small amounts of cannabis, setting the stage for reform in Texas. The act, which passed with 65% support, prohibits arrests for possession of up to 4 ounces of cannabis and restricts the police from using cannabis odor as probable cause. 
Local advocacy group Ground Game Texas celebrated the victory, stating, "This is more than a victory for marijuana decriminalization—it's a win for the people of Dallas." The success in Dallas reflects a growing trend in Texas cities to pursue cannabis reform, even as state-level opposition continues.
<h2 class="wp-block-heading">Cannabis Stocks Fall After 2024 Election</h2>
In response to these election outcomes, U.S.-focused cannabis stocks and ETFs are trading down in Wednesday&#8217;s pre-market session. Notably, Verano Holdings Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>), Curaleaf Holdings Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), Green Thumb Industries Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) and Trulieve Cannabis Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) have experienced sharp declines, along with ETFs such as the AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) and Amplify Alternative Harvest ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MJ#NYSE">MJ</a>), most trading down by double digits.
As cannabis legalization and decriminalization efforts advance, the varied responses across states showcase an evolving but complex landscape. With each election, states signal their readiness, or reluctance, to embrace cannabis reform, reflecting both local values and national debates.
Cover image made with AI

Cannabis

Politics

Legal

Movers

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

MSOS

NLCP

TCNNF

VRNOF

Cannabis Reform Stumbles In 2024 Elections: A State-By-State Breakdown As Stocks Take A Hit

KRNT

Kornit Digital shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 revenue guidance above estimates.

The U.S. Dollar Index (DXY) recorded its sharpest one-day rally in over eight years on Wednesday as Donald Trump secured victory in <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">the 2024 presidential election. </a>
This currency-weighted gauge of the dollar – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – jumped nearly 1.8% in early New York trading, marking the steepest rise since June 24, 2016, when the British pound plummeted following the Brexit referendum, sparking a similar dollar spike.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083511/image-50-1024x501.png" alt="" class="wp-image-632773" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083511/image-50-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083511/image-50-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083511/image-50-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083511/image-50-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083511/image-50.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Global Forex Markets Face Wild Moves As Trump Return To White House</h3>
The dollar surged across the board, with notable gains against the euro, Chinese yuan and Mexican peso amid market concerns over potential U.S. trade tariffs under the Trump administration.
The euro, tracked by the Invesco CurrencyShares Euro Currency Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXE#NYSE">FXE</a>), fell below $1.07, down over 2.1% in its worst session since March 2020. 
Last week, JPMorgan had projected that <a href="https://www.benzinga.com/markets/24/11/41741466/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan">a Republican clean sweep could weaken the euro</a> by as much as 8.4%, with analysts citing a potential widening in the U.S.-EU monetary policy gap. Higher inflation in the U.S. may prompt the Federal Reserve to maintain or hike interest rates, while the European Central Bank (ECB) could face pressure to cut rates, analysts said.
The Chinese yuan also took a hit, declining 1.2%, hitting 7.1960 — its largest drop in two years. Trump's promise to impose tariffs as high as 60% on Chinese imports fueled concerns of escalating trade tensions.
&#8220;The 7.2000 level is a critical psychological threshold, which, if breached, could prompt intervention by Chinese monetary authorities," highlighted Luca Cigognini, market strategist at Banca IMI.
The Mexican peso was another major losers, slumping 2.7% to its lowest level since August 2022. 
"We anticipate that some pragmatism will prevail, with partial reversals in the medium term," said Alejandro Cuadrado, chief market strategist at BBVA.
Meanwhile, the Canadian dollar, though down 0.8% against the greenback, outperformed other major currencies. 
"A Republican clean sweep bodes well for U.S. economic growth and Canadian exporters," said Francesco Pesole, foreign exchange analyst at ING Group, adding that Canada's currency remains relatively insulated from U.S.-China tariff dynamics and geopolitical risks under a Trump presidency.
Below is a snapshot of U.S. dollar movements against major currencies as of Wednesday morning:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>USD vs.</td>
<td>Last</td>
<td>1-day chg (%)</td>
</tr>
<tr>
<td>Mexican Peso (MXN)</td>
<td>20.62843</td>
<td>2.61%</td>
</tr>
<tr>
<td>Euro (EUR)</td>
<td>0.9339</td>
<td>2.10%</td>
</tr>
<tr>
<td>Japanese Yen (JPY)</td>
<td>154.201</td>
<td>1.71%</td>
</tr>
<tr>
<td>Swiss Franc (CHF)</td>
<td>0.87582</td>
<td>1.50%</td>
</tr>
<tr>
<td>British Pound (GBP)</td>
<td>0.77760</td>
<td>1.42%</td>
</tr>
<tr>
<td>Chinese Yuan (CNH)</td>
<td>7.193730</td>
<td>1.32%</td>
</tr>
<tr>
<td>Australian Dollar (AUD)</td>
<td>1.5230</td>
<td>1.14%</td>
</tr>
<tr>
<td>New Zealand Dollar (NZD)</td>
<td>1.6818</td>
<td>1.04%</td>
</tr>
<tr>
<td>Brazilian Real (BRL)</td>
<td>5.7947</td>
<td>0.76%</td>
</tr>
<tr>
<td>Canadian Dollar (CAD)</td>
<td>1.39276</td>
<td>0.75%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 9:15 a.m. ET </figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41769412/dow-nasdaq-futures-race-higher-as-trump-wins-white-house-djt-tesla-shares-surge-veteran-investor-pr">Dow, Nasdaq Futures Race Higher As Trump Wins White House: DJT, Tesla Shares Surge — Veteran Investor Predicts US Economy Could &#8216;Take Off&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Emerging Markets

Currency ETFs

Forex

Global

Econ #s

Federal Reserve

ETFs

PowerShares DB US Dollar Index Bullish Fund

Dollar Index Sees Biggest 1-Day Rally Since Brexit On Trump Victory

Lisata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Valo Therapeutics Oy ("ValoTx"), a private company developing novel, adaptable immunotherapies for the treatment of cancer, are pleased to announce a preclinical research collaboration to investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's innovative platform technology, PeptiCRAd, and a checkpoint inhibitor in a melanoma mouse model. Under the agreement, ValoTx will be conducting the research, while Lisata will supply certepetide product.

Biotech

General

LSTA

Lisata Therapeutics And Valo Therapeutics Announce Preclinical Research Collaboration To Investigate The Benefits Of Combining Lisata's Novel Product Candidate, Certepetide, With ValoTx's Innovative Platform Technology, PeptiCRAd, And A Checkpoint Inhibitor In A Melanoma Mouse Model

RYAM

Rayonier Advanced Materials shares are trading higher. The company reported Q3 financial results.

Hut 8 Corp shares are trading higher after the company announced an initial ASIC fleet upgrade.

CANG

Golden TechGen Expected To Be The Largest Seller In These Transactions, Will Own No More Than 20% Of Cango's Total Outstanding Shares, And All The Sellers In The Share-Settled Transactions Will In The Aggregate Own ~37.8% Of The Co's Total Outstanding Shares

The Scotts Miracle-Gro Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) announced its results Wednesday for the full year and fourth quarter ended Sept. 30, 2024.
"Fiscal 2024 was a strong transition year for the Company in which we continued to transform the business while achieving meaningful top-and bottom-line growth in our core business," said Matt Garth, the company's CFO and chief administrative officer. "We made strategic investments in marketing and innovation to drive sales and support the long-term health of our brands powered by additional efficiency gains across our organization."
Net sales for the company's subsidiary for cannabis growers, Hawthorne Gardening Company, decreased 46% year-over-year to $80.5 million in the fourth quarter of fiscal 2024. The Ohio-based gardening giant reported this trend in <a href="https://www.benzinga.com/markets/cannabis/24/07/40075102/scotts-miracle-gros-cannabis-focused-subsidiary-reports-28-yoy-drop-in-q3-net-sales-reaffirms-20">the previous quarter</a> as well, which it attributed to the previously announced discontinuation of its third-party distributed brands business.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/39094250/this-cannabis-merger-will-cover-25-of-u-s-population-cansortium-riv-capital-powered-by-scottsmir">This Cannabis Merger Will Cover 25% Of U.S. Population: Cansortium &amp; RIV Capital Powered By ScottsMiracle-Gro</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Q4 2024 Financial Highlights</h3>
<ul>
<li>Total company net sales were $414.7 million, an increase of 11% from $374.5 million in the same quarter last year.</li>
<li>U.S. consumer net sales increased 54% year-over-year to $309.7 million.</li>
<li>Hawthorne segment sales decreased 46% year-over-year, to $80.5 million.</li>
<li>GAAP and non-GAAP adjusted gross margin rates for the quarter were negative 7.1% and negative 3.1%, respectively, compared to negative 15.2 percent and negative 8.8 percent, respectively, in the prior year's period.</li>
<li>GAAP net loss of $244 million, or $4.29 per share, compared with the prior year's fourth-quarter loss of $468.4 million, or $8.33 per share.</li>
<li>Non-GAAP adjusted net loss for the quarter, which excludes impairment, restructuring and other non-recurring items, was a loss of $131.5 million, or $2.31 per share, compared to a loss of $155.4 million, or $2.77 per share, for the same period last year.</li>
</ul>
<h3 class="wp-block-heading">FY 2024 Financial Highlights</h3>
<ul>
<li>Total net sales were roughly flat compared to the prior year at $3.6 billion.</li>
<li>U.S. Consumer segment sales increased 6% year-over-year, to $3 billion, driven by incremental shelf space, new listings and promotions mainly in the gardens and controls businesses.</li>
<li>Sales for the Hawthorne segment decreased 37% year-over-year to $294.7 million, primarily due to the discontinuation of its third-party distribution business.</li>
<li>The company-wide gross margin rate was 23.9% on a GAAP basis and 26.3% on a non-GAAP adjusted basis compared with rates of 18.5% and 23.7%, respectively, a year ago.</li>
<li>Selling, general and administrative expenses of $559 million were 15.7% of net sales, a 9% decrease from fiscal 2022 reflecting the company's previously announced cost-reduction efforts.</li>
<li>Other operating expenses were $19.9 million primarily due to the discount cost on sales of accounts receivable under the company's accounts receivable sale agreement.</li>
<li>GAAP net loss was $34.9 million, or $0.61 per share, compared with a loss of $380.1 million, or $6.79 per share, in the prior year.</li>
<li>Non-GAAP adjusted EBITDA was $510.1 million for fiscal 2024 including one-time charges of $29 million related to the AeroGarden write-down and other items, compared to $446.9 million last year.</li>
<li>Free cash flow for fiscal 2024 was $583.5 million, compared to $438.2 million a year ago.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39251909/class-action-lawsuit-against-scotts-miracle-gro-investors-allege-misleading-information-and-arti">Class Action Lawsuit Against Scotts Miracle-Gro: Investors Allege &#8216;Misleading Information&#8217; And &#8216;Artificially Inflated Prices&#8217;</a></li>
</ul>
<h3 class="wp-block-heading">SMG Price Action</h3>
The Scotts Miracle-Gro Company's shares traded 4.78% lower at $89 per share during the pre-market session on Wednesday morning.

Gardening Giant Scotts Miracle-Gro Reports 46% YoY Drop In Q4 Net Sales For Its Cannabis-Focused Subsidiary

BTBT

Bit Digital shares are trading higher after the company announced growing monthly production updates for October which led to 52.2 BTC produced.

Cango Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) ("Cango" or the "Company"), a leading automotive transaction service platform in China, today announced that it has entered into agreements to purchase on-rack crypto mining machines with an aggregate hashrate of 50 Exahash per second ("EH") for total considerations valued at approximately US$400 million from a group of sellers. The largest seller will be Bitmain Technologies Georgia Limited and Bitmain Development Limited (together, "Bitmain"), a leading manufacturer of digital currency mining servers, and the Company has agreed to purchase from Bitmain on-rack crypto mining machines with an aggregate hashrate of 32EH for a total purchase price of US$256 million in cash (the "Cash-Settled Transaction"). The Company has also agreed to purchase the remaining on-rack crypto mining machines with an aggregate hashrate of 18EH from Golden TechGen Limited ("GT"), a company incorporated under the laws of the British Virgin Islands and wholly owned by Mr. Max HUA ("Mr. Hua"), former chief financial officer of Bitmain and the sole shareholder of GT, and certain other sellers, and will pay the purchase price through issuance of an aggregate of approximately 145,658,192 Class A ordinary shares of the Company (valued at US$144 million) to the sellers in proportion to the aggregate hashrate of the machines to be sold by each seller (the "Share-Settled Transactions", and together with the Cash-Settled Transaction, the "Proposed Transactions").
Upon closing of the Share-Settled Transactions, GT, which is expected to be the largest seller in these transactions, will own no more than 20% of the Company's total outstanding shares, and all the sellers in the Share-Settled Transactions will in the aggregate own approximately 37.8% of the Company's total outstandings shares before any exercise of the warrants described below.&nbsp; The Company also agreed to grant Mr. Hua the right to nominate and appoint two directors of the Company until Mr. Hua and his affiliates cease to hold more than 5% of the Company's total outstanding shares. If the market capitalization of the Company calculated based on the daily volume-weighted average trading price of the Company's ADSs over any consecutive 30-trading days during the 30-month period after closing of the Share-Settled Transactions reaches US$1,825,000,000 (the "Bonus Triggering Event"), the Company agreed to issue at par value approximately 97,105,461 additional Class A ordinary shares to all the sellers in the Share-Settled Transactions as bonus payment in proportion to the aggregate hashrate of the machines to be sold by each seller, and the Company agreed to issue warrants to the sellers that will allow them to exercise such rights within 3 months after the Bonus Triggering Event. &nbsp;Furthermore, if the net asset value (after certain adjustments) of the Company's existing business in China is reduced by RMB50 million or more by the end of 2026 as compared to such value as of September 30, 2024 (the "Adjustment Event"), the Company will be required to issue additional Class A ordinary shares to the Sellers based on the reduced amount. While all the Class A ordinary shares will be issued to the sellers in transactions that are not subject to or exempted from the registration requirement of the U.S. Securities Act of 1933, the Company has granted certain registration rights to the sellers with respect to the shares. The Company will seek shareholders' approval to amend its memorandum and articles of association to increase the Company's total authorized share capital as necessary to effect any share issuance, including under the Bonus Triggering Event or Adjustment Event. As the Company's co-founders, Mr. Xiaojun Zhang and Mr. Jiayuan Lin (the "Co-founders"), will continue to own all the Class B ordinary shares of the Company with super-voting power, the Co-founders are expected to continue to own more than two-thirds of the aggregate voting power of the Company's total outstanding shares (assuming full exercise of the warrants described above) and maintain their control over the Company after completion of the Proposed Transactions.&nbsp;

Cango Enters Into Agreements To Purchase On-Rack Crypto Mining Machines With An Aggregate Hashrate Of 50 EH/s For Total Considerations Valued At ~$400M From A Group Of Sellers

A top mortgage industry executive issued a message to Washington lawmakers this week, calling for immediate action to address <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39614880/now-owning-a-house-in-us-is-more-challenging-than-ever-as-affordability-drops-to-">America&#8217;s mounting housing affordability crisis</a>.
Laura Escobar, newly appointed chair of the Mortgage Bankers Association and president of Lennar Mortgage, told industry leaders at the MBA&#8217;s annual conference in Denver that the American dream of homeownership is slipping away from an increasing number of families.
Don't Miss:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
&#8220;We&#8217;re on the verge of a vicious cycle, in which fewer and fewer people can afford the American dream of homeownership. That&#8217;s not good for America,&#8221; Escobar said Monday, addressing the trade group&#8217;s 275,000 members.
The housing shortage has reached critical levels, with the U.S. facing a deficit of 1.5 million homes, according to Escobar. She pointed to <a href="https://www.benzinga.com/real-estate/24/09/41082529/its-not-a-housing-crisis-but-a-housing-policy-crisis-homebuilders-call-out-roadblocks-as-prices-surg">decades of regulatory barriers that have made it increasingly difficult to construct new homes or renovate existing ones</a>, particularly for smaller builders.
Government regulations add nearly $94,000 to the average price of a new home, according to Market Watch, which cited a 2021 National Association of Home Builders study. Construction costs have risen sharply, with labor and materials expenses jumping 31% since the start of the COVID pandemic.
See Also: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
The impact of the constraints is evident in markets nationwide. In Las Vegas, 34-year-old Andy Balmert spent eight months searching for a home before finally purchasing a two-bedroom condo, made possible only through a $50,000 grant program targeting middle-class buyers.
&#8220;Not as many are wanting to buy houses. But even those who want to simply can&#8217;t without some sort of assistance,&#8221; Justin Jones, a Clark County commissioner, said to Bloomberg.
Restrictive zoning laws compound the problem, with roughly 75% of residential land in the U.S. restricted to single-family homes, Escobar noted. She plans to campaign for loosening regulations in mortgage lending and home building.
The crisis has particularly affected middle-income households. Federal loan data cited by Bloomberg shows that 58% of mid-income households approved for mortgages last year had debt-to-income ratios exceeding 40%, which is the highest level since at least 2018.
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
&#8220;Enough is enough,&#8221; Escobar said. &#8220;My message to every policy maker in Washington D.C. is going to be simple. Stop talking about affordability — and start delivering on affordability.&#8221;
Market conditions remain challenging, with 30-year mortgage rates hovering near 7% and home prices at record levels. According to Fannie Mae, returning to 2016-2019 affordability levels would require either a 38% drop in median home prices, a 60% increase in median household income, or mortgage rates falling to 2.35%.
As the housing crisis moves to the center of national politics, both major presidential candidates have proposed solutions. However, some experts remain skeptical about federal intervention&#8217;s effectiveness.
&#8220;The focus has to be on the supply side,&#8221; Mark Fleming, chief economist at First American Financial Corp, said to Bloomberg. &#8220;The challenge is that there&#8217;s not a lot that the federal government can do. A lot of it is sort of local zoning, local regulatory hurdles.&#8221;
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Real Estate

'Stop Talking About Affordability' — Real Estate Exec Calls On Lawmakers To Act On Housing Costs

Qualcomm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) will release earnings results for its fourth quarter, after the <a href="https://www.benzinga.com/quote/qcom/earnings">closing bell on Wednesday, Nov. 6.</a>
Wall Street expects the San Diego, California-based company to report quarterly earnings at $2.56 per share, up from $2.02 per share in the year-ago period. The company projects to report revenue of $9.9 billion, compared to $8.66 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Tuesday, JPMorgan analyst Samik Chatterjee maintained Qualcomm with an Overweight and lowered the price target from $210 to $195.
With the recent buzz around Qualcomm ahead of quarterly earnings, some investors may be eyeing potential gains from the company's dividends, too. Qualcomm currently offers an annual dividend yield of 2.05%. That&#8217;s a quarterly dividend amount of 85 cents per share ($3.40 a year).
To figure out how to earn $500 monthly from Qualcomm, we start with a yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Qualcomm's $3.40 dividend: $6,000 / $3.40 = 1,765 shares.
So, an investor would need to own approximately $292,831 worth of Qualcomm, or 1,765 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $3.40 = 353 shares, or $58,566 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
Price Action: Shares of Qualcomm gained by 0.4% to close at $165.91 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

How To Earn $500 A Month From Qualcomm Stock Ahead Of Q4 Earnings

BTDR

Bitdeer Technologies shares are trading higher after the company announced October 2024 production and operations updates which led to 174 self-mined Bitcoins.

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) with a Buy and lowers the price target from $15 to $14.

VERV

HC Wainwright & Co. Maintains Buy on Verve Therapeutics, Lowers Price Target to $14

Neonode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEON#NASDAQ">NEON</a>) reported quarterly losses of $(0.07) per share. This is unchanged from the same period last year. The company reported $800.00 thousand in sales this quarter. This is a 20.24 percent decrease over sales of $1.00 million the same period last year.

NEON

Neonode Q3 EPS $(0.07), Same YoY, Sales $800.00K Down From $1.00M YoY

Globus Medical ( ($GMED) ) has released its Q3 earnings. Here is a breakdown of the information Globus Medical presented to its investors. Globus M...

Globus Medical Reports Robust Q3 2024 Financial Growth

BTIG analyst Ryan Zimmerman maintained a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of $87.00. The company'...

BTIG Sticks to Its Buy Rating for Globus Medical (GMED)

Wells Fargo analyst Vik Chopra raised the firm's price target on Globus Medical (GMED) to $88 from $78 and keeps an Overweight rating on the shares...

Globus Medical price target raised to $88 from $78 at Wells Fargo

Wells Fargo analyst Vik Chopra has assigned their bullish stance on GMED stock, giving a Buy rating yesterday. Vik Chopra has given his Buy rating ...

Globus Medical's Strong Q3 Performance and Optimistic Outlook Justify Buy Rating

Truist Financial analyst Richard Newitter maintained a Hold rating on Globus Medical (GMED – Research Report) today and set a price target of $85.0...

Truist Financial Sticks to Its Hold Rating for Globus Medical (GMED)

Piper Sandler Reaffirms Their Buy Rating on Globus Medical (GMED)

Piper Sandler analyst Matt O'Brien raised the firm's price target on Globus Medical (GMED) to $100 from $80 and keeps an Overweight rating on the s...

Globus Medical price target raised to $100 from $80 at Piper Sandler

Stifel analyst Mathew Blackman raised the firm's price target on Globus Medical (GMED) to $92 from $80 and keeps a Buy rating on the shares. Q3 "se...

Globus Medical price target raised to $92 from $80 at Stifel

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – CVS Health (CVS) up 12% Vertex (VERX) up 6% I...

Morning Movers: CVS Health surges and ODP sinks following Q3 results

RBC Capital raised the firm's price target on Globus Medical (GMED) to $92 from $80 and keeps an Outperform rating on the shares. The company issue...

Globus Medical price target raised to $92 from $80 at RBC Capital

ATHM

AUDC

CELH

ENOV

EXAS

HNDAF

IONS

IRBT

VERX

Press Releases

Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Domino's and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED

GMED Investors Have Opportunity to Join Globus Medical, Inc. Securities Fraud Investigation with the Schall Law Firm

Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Metagenomi and Encourages Investors to Contact the Firm

Globus Medical Launches the Next Wave of Orthopedic Trauma Solutions

Globus Medical Schedules Third Quarter Earnings Release and Conference Call

Health Care

Globus Medical to Participate in Orthopedic Trauma Association Annual Meeting

Globus Medical Reports Third Quarter 2024 Results

CUBI

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Piper Sandler

B of A Securities

BTIG

RBC Capital

Barclays

Globus Medical shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance above estimates.

Comments

Globus Medical

Globus Medical (GMED) 옵션

Globus Medical (NYSE:GMED) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌